Table 1.
Demographic and baseline disease characteristicsa
| Characteristic | Plecanatide 3 mg (n = 877) | Plecanatide 6 mg (n = 877) | Placebo (n = 885) |
| Age, yr | |||
| Mean (SD) | 45.3 (14.6) | 45.1 (14.1) | 45.5 (14.3) |
| Range | 18–80 | 18–80 | 18–80 |
| Female, n (%) | 698 (79.6) | 708 (80.7) | 697 (78.8) |
| Race/ethnicity, n (%) | |||
| White | 632 (72.1) | 617 (70.4) | 647 (73.1) |
| Black | 211 (24.1) | 206 (23.5) | 194 (21.9) |
| Asian | 20 (2.3) | 29 (3.3) | 27 (3.1) |
| Other | 14 (1.6) | 25 (2.9) | 17 (1.9) |
| Mean BMI, kg/m2 (SD) | 28.4 (5.0) | 28.3 (5.1) | 28.0 (5.2) |
| BMI subgroup, n (%) | |||
| Underweight/normal (<25 kg/m2) | 234 (26.7) | 246 (28.1) | 275 (31.1) |
| Overweight (25 to <30 kg/m2) | 356 (40.6) | 332 (37.9) | 333 (37.6) |
| Obese (≥30 kg/m2) | 287 (32.7) | 299 (34.1) | 277 (31.3) |
| Mean number of SBMs per wk (SD) | 1.9 (1.9) | 1.7 (1.7) | 1.9 (1.8) |
| Mean number of CSBMs per wk (SD) | 0.3 (0.6) | 0.3 (0.5) | 0.4 (0.5) |
BMI, body mass index; CSBM, complete spontaneous bowel movement; SBM, spontaneous bowel movement.
a
Intention-to-treat population.